Managing nonalcoholic fatty liver disease in atients living with HIV

Current Opinion in Infectious Diseases

Volumn 30, Issue 1, 2017, Pages 12-20

  Tafesh, Zaid H ^a   Verna, Elizabeth C ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

HIV; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Treatment

Indexed keywords

ANTIRETROVIRAL THERAPY; DIET; DISEASE COURSE; DYSLIPIDEMIA; ELASTOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER FIBROSIS; LIVER TOXICITY; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; RISK FACTOR; WEIGHT REDUCTION; COMPLICATION; FATTY LIVER;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTI-HIV AGENTS; DYSLIPIDEMIAS; FATTY LIVER; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 85004025706     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000344     Document Type: Review

References (65)

1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34:274-285.
2. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142:1592-1609.
3. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease - meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64:73-84.
4. Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 2014; 384:241-248.
5. Soriano V, Barreiro P, Sherman KE. The changing epidemiology of liver disease in HIV patients. AIDS Rev 2013; 15:25-31.
6. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of nonalcoholic fatty liver disease (NAFLD) and diagnostic accuracy of noninvasive tests for liver disease severity. Ann Med 2011; 43:617-649.
7. Hannah WN Jr, Harrison SA. Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2016; 64:2234-2243.
8. Noureddin M, Lam J, Peterson MR, et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 2013; 58:1930-1940.
9. Schneiderman DJ, Arenson DM, Cello JP, et al. Hepatic disease in patients with the acquired immune deficiency syndrome (AIDS). Hepatology 1987; 7:925-930.
10. Lebovics E, Thung SN, Schaffner F, Radensky PW. The liver in the acquired immunodeficiency syndrome: a clinical and histologic study. Hepatology 1985; 5:293-298.
11. Price JC, Seaberg EC, Latanich R, et al. Risk factors for fatty liver in the Multicenter AIDS Cohort Study. Am J Gastroenterol 2014; 109:695-704.
12. Morse CG, McLaughlin M, Matthews L, et al. Nonalcoholic steatohepatitis and hepatic fibrosis in HIV-1-monoinfected adults with elevated aminotransferase levels on antiretroviral therapy. Clin Infect Dis 2015; 60: 1569-1578.
13. Crum-Cianflone N, Dilay A, Collins G, et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr 2009; 50:464-473.
14. Hadigan C, Liebau J, Andersen R, et al. Magnetic resonance spectroscopy of hepatic lipid content and associated risk factors in HIV infection. J Acquir Immune Defic Syndr 2007; 46:312-317.
15. Guaraldi G, Squillace N, Stentarelli C, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis 2008; 47:250-257.
16. Nishijima T, Gatanaga H, Shimbo T, et al. Traditional but not HIV-related factors are associated with nonalcoholic fatty liver disease in Asian patients with HIV-1 infection. PLoS One 2014; 9:e87596.
17. Macias J, Gonzalez J, Tural C, et al. Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients. AIDS 2014; 28:1279-1287.
18. SulyokM,MakaraM, Rupnik Z, et al. Hepatic steatosis in individuals living with HIV measured by controlled attenuation parameter: a cross-sectional study. Eur J Gastroenterol Hepatol 2015; 27:679-685.
19. Sterling RK, Smith PG, Brunt EM. Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse. J Clin Gastroenterol 2013; 47:182-187.
20. Li Vecchi V, Giannitrapani L, Di Carlo P, et al. Noninvasive assessment of liver steatosis and fibrosis in HIV/HCV- and HCV-infected patients. Ann Hepatol 2013; 12:740-748.
21. Lui G, Wong VW, Wong GL, et al. Liver fibrosis and fatty liver in Asian HIVinfected patients. Aliment Pharmacol Ther 2016; 44:411-421.
22. Mohammed SS, Aghdassi E, Salit IE, et al. HIV-positive patients with nonalcoholic fatty liver disease have a lower body mass index and are more physically active than HIV-negative patients. J Acquir Immune Defic Syndr 2007; 45:432-438.
23. Vuille-Lessard E, Lebouche B, Lennox L, et al. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients. AIDS 2016; 30:2635-2643.
24. Lombardi R, Sambatakou H, Mariolis I, et al. Prevalence and predictors of liver steatosis and fibrosis in unselected patients with HIV mono-infection. Dig Liver Dis 2016. [Epub ahead of print]
25. Ingiliz P, Valantin MA, Duvivier C, et al. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology 2009; 49:436-442.
26. Vodkin I, Valasek MA, Bettencourt R, et al. Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study. Aliment Pharmacol Ther 2015; 41:368-378. Although the natural history of NAFLD among patients with HIV is not described, this article suggests that these patients may be at higher risk of the more aggressive forms of the disease, including NASH and fibrosis, compared with matched controls with NAFLD in the general population.
27. Macias J, Real LM, Rivero-Juarez A, et al. Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIVinfected patients. HIV Med 2016; 17:766-773.
28. Crum-Cianflone N, Krause D, Wessman D, et al. Fatty liver disease is associated with underlying cardiovascular disease in HIV-infected persons. HIV Med 2011; 12:463-471.
29. Rinella ME, Sanyal AJ. Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol 2016; 13:196-205. This is a well written and succinct review of the current approach to NAFLD treatment, based upon the disease stage. Although this review does not include recommendations specifically for patients with NAFLD and HIV, it provides important insights into the current landscape of treatment in the general population.
30. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of nonalcoholic fatty liver disease (NAFLD). Metabolism 2016; 65: 1038-1048.
31. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015; 62 (1 Suppl):S47-S64.
32. Li Vecchi V, Soresi M, Giannitrapani L, et al. Prospective evaluation of hepatic steatosis in HIV-infected patients with or without hepatitis Cvirus co-infection. Int J Infect Dis 2012; 16:e397-e402.
33. Bilal U, Lau B, Lazo M, et al. Interaction between alcohol consumption patterns, antiretroviral therapy type, and liver fibrosis in persons living with HIV. AIDS Patient Care STDS 2016; 30:200-207.
34. Lui G, Wong VW, Wong GL, et al. Liver fibrosis and fatty liver in Asian HIVinfected patients. Aliment Pharmacol Ther 2016; 44:411-421.
35. Nunez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 2010; 52:1143-1155.
36. Worm SW, Friis-Moller N, Bruyand M, et al. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS 2010; 24:427-435.
37. de Waal R, Cohen K, Maartens G. Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS One 2013; 8:e63623.
38. Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol 2016; 13:412-425.
39. Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2016; 63:764-775.
40. Nowak P, Troseid M, Avershina E, et al. Gut microbiota diversity predicts immune status in HIV-1 infection. AIDS 2015; 29:2409-2418.
41. Marchetti G, Tincati C, Silvestri G. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev 2013; 26:2-18.
42. Younossi ZM, Reyes MJ, Mishra A, et al. Systematic review with meta-analysis: nonalcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther 2014; 39:3-14.
43. Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13:643-654.e1- e9; quiz e39-e40.
44. Eckard C, Cole R, Lockwood J, et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Ther Adv Gastroenterol 2013; 6:249-259.
45. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 2000; 22:911-936; discussion 898.
46. Macias J, Berenguer J, Japon MA, et al. Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. Hepatology 2012; 56:1261-1270.
47. AASLD 2016 [cited 2016 September 28]. Available from: http://hcvguidelines.org/.
48. Federico A, Dallio M, Godos J, et al. Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence. Transl Res 2016; 167:116-124.
49. Gangarapu V, Ince AT, Baysal B, et al. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2015; 27:840-845.
50. Tenorio AR, Chan ES, Bosch RJ, et al. Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune nonresponders to antiretroviral therapy - ACTG A5286. J Infect Dis 2015; 211:780-790.
51. Noureddin M, Anstee QM, Loomba R. Review article: emerging antifibrotic therapies in the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2016; 43:1109-1123.
52. Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for nonalcoholic fatty liver disease. Gut 2016. [Epub ahead of print]
53. Arab JP, Karpen SJ, Dawson PA, et al. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology 2016. [Epub ahead of print]
54. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362:1675-1685.
55. Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142:37-46.
56. Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306:1549-1556.
57. Cui J, Philo L, Nguyen P, et al. Sitagliptin vs. placebo for nonalcoholic fatty liver disease: a randomized controlled trial. J Hepatol 2016; 65:369-376.
58. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic, nonalcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385:956-965.
59. Ratziu V, Harrison SA, Francque S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic ateatohepatitis without fibrosis worsening. Gastroenterology 2016; 150:1147-1159 e5.
60. Kleiner DE, Bedossa P. Liver histology and clinical trials for nonalcoholic steatohepatitis-perspectives from 2 pathologists. Gastroenterology 2015; 149:1305-1308.
61. Singh S, Khera R, Allen AM, et al. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: a systematic review and network meta-analysis. Hepatology 2015; 62:1417-1432.
62. Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA 2014; 312:380-389.
63. Safadi R, Konikoff FM, Mahamid M, et al. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014; 12:2085-2091.e1.
64. Thompson M, Saag M, DeJesus E, et al. A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus. AIDS 2016; 30:869-878.
65. Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol 2015; 62 (1 Suppl):S65-S75.